ArticleCardiovascular diagnosis and therapy2026
Comparison of safety and long-term outcomes of retrograde chronic total occlusion percutaneous coronary intervention in patients with
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The safety profile and long-term outcomes of retrograde percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in patients with diabetes mellitus (DM) remain inadequately characterized. We evaluated procedural and extended follow-up results in this cohort. Methods: This single-center retrospective study enrolled adults undergoing retrograde CTO-PCI; individuals with incomplete data, malignancy, or end-stage renal disease were excluded. Primary and secondary outcomes were all-cause mortality and major adverse cardiovascular events (MACE), respectively. Intergroup comparisons used standard univariate tests. Cumulative hazard functions were estimated via the Nelson-Aalen method, and multivariable Cox proportional hazards models were performed to adjust for clinical confounders and identify variables associated with MACE. Results: In total, 836 patients met the criteria. Success rates for collateral channel (CC) tracking (92.0% in the DM group Conclusions: Retrograde PCI is technically safe and effective in CTO patients with DM. However, this cohort carries a significantly higher long-term risk of mortality and MACE than non-diabetic counterparts, necessitating intensified post-procedural risk-factor management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.